(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 75.21% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Agios Pharmaceuticals's revenue in 2026 is $98,338,000.On average, 12 Wall Street analysts forecast AGIO's revenue for 2026 to be $11,087,236,506, with the lowest AGIO revenue forecast at $9,712,302,164, and the highest AGIO revenue forecast at $13,603,073,814. On average, 12 Wall Street analysts forecast AGIO's revenue for 2027 to be $21,308,198,705, with the lowest AGIO revenue forecast at $12,991,726,542, and the highest AGIO revenue forecast at $26,838,981,053.
In 2028, AGIO is forecast to generate $31,591,847,879 in revenue, with the lowest revenue forecast at $23,884,931,932 and the highest revenue forecast at $42,295,201,284.